New CT-guided radiotherapy system offers personalised cancer treatment
Berlin’s Diagnostisch Therapeutisches Zentrum (DTZ) has become the first in the world to treat a patient using Elekta Evo, an AI-powered adaptive CT-Linac.
The 62-year-old male patient is receiving curative treatment for bladder cancer, marking a significant advancement in personalised cancer care.
“With Iris, CBCT image quality has improved significantly thanks to AI-enhanced image reconstruction,” said Dr Matthias Lampe, Radiation Oncologist and partner at DTZ. “This gives us greater confidence and saves time, improving both the quality of treatment and patient comfort. Additionally, Evo allows real-time treatment planning with online adaptive radiation therapy.”
Evo combines high-definition, AI-enhanced imaging, enabling faster dose calculation and AI-driven automation for contouring and dose planning.
This technology offers clinicians the ability to visualise tumours and organs-at-risk with exceptional clarity, making personalised radiation therapy more effective.
“DTZ has a reputation for providing the latest diagnostic and therapeutic oncology technology, and we’re proud that our solutions have contributed to that success,” said Gustaf Salford, Elekta President and CEO.
He added that Evo is facilitating personalised radiotherapy for cancer patients, with more sites expected to begin treatments soon.
Traditional surgery for bladder cancer can be invasive and significantly impact quality of life. By choosing radiation therapy with Elekta Evo, the patient has opted for a less invasive treatment that offers high precision.
Elekta Evo is part of DTZ’s comprehensive radiotherapy offerings, which include five state-of-the-art linear accelerators and a range of Elekta ONE software solutions.
This system’s ability to offer online and offline plan adaptation, as well as improved image-guided radiation therapy, allows clinicians to select the most suitable technique for each patient’s case.
Salford concluded, “We’re committed to providing the best imaging and treatment tools, and it is satisfying to see how Evo is making personalised radiotherapy a reality for cancer patients.”
